Fri, Jul 11, 2014, 4:55 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Dick's Sporting Goods Inc. Message Board

sherrysgone 65 posts  |  Last Activity: Jun 12, 2014 2:35 PM Member since: Feb 11, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    buy topotarget

    by boogaloozzz Jun 11, 2014 11:11 AM
    sherrysgone sherrysgone Jun 12, 2014 2:35 PM Flag

    Yep, I'm sure Charger & Stockstoshort are sorry they got you into UPRO @ $113.00+ and CNAT @ $9. Way to go pumpers!!! Woo hoo hoo.....hanging on to my SPPI. Who knows, we may be bought out by the time I get home the end of September! Sure glad I didn't listen to these two losers when I bought a bunch of SPPI in the mid $6's.

    Cheers and bye for the summer!!!!!!!!!!!!!!!!!!

    Sherry

    Sentiment: Strong Buy

  • Reply to

    Jeffries Presentation....

    by ouch_yikes Jun 4, 2014 11:04 AM
    sherrysgone sherrysgone Jun 4, 2014 1:48 PM Flag

    I agree too.....only hope I'll still be around in 2016 (*~^)! Leaving soon for the summer, so will leave SPPI in the hands of the great MB posters for any valuable news, as I will only occasionally be able to check in. Am REALLY looking forward to good news for SPPI in August!! Appreciate all the interesting and very worthy things many of you post on here.

    Have a wonderful summer, everyone!!!

    Sherry

    Sentiment: Strong Buy

  • Reply to

    Revised Presentation

    by antihama2001 May 27, 2014 8:47 PM
    sherrysgone sherrysgone May 27, 2014 11:53 PM Flag

    Thank you, antihama!

    Sentiment: Strong Buy

  • Spectrum Pharmaceuticals Given Consensus Rating of “Buy” by Brokerages (NASDAQ:SPPI)

    Posted by Joseph Griffin on May 21st, 2014 // No Comments

    Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals (NASDAQ:SPPI) has earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, Stock Ratings News reports. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.57.

    Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Spectrum Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, May 7th. They now have a $7.40 price target on the stock. Analysts at TheStreet downgraded shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 7th.

    Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 7.66 on Wednesday. Spectrum Pharmaceuticals has a 52 week low of $6.36 and a 52 week high of $10.32. The stock’s 50-day moving average is $7.17 and its 200-day moving average is $8.34. The company’s market cap is $486.0 million.

    Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its earnings data on Thursday, May 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.23. The company had revenue of $40.10 million for the quarter, compared to the consensus estimate of $39.49 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts predict that Spectrum Pharmaceuticals will post $-0.70 earnings per share for the current fiscal year.

    Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology.

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 17, 2014 2:58 PM Flag

    I have mentioned these characters B4, hopefullylong and agree that the SEC should be checking out their trading in SPPI. Millenium, and Deerfield both have a HIGH turnover rating and GS has a moderate turnover rating on their ownership in SPPI according to CNBC ownership stats. Just look at this 13G/A filed by Integrated Core Strategies, Delaware, on 12/31/2013 & rec'd. 1/17/2014, wherein there are shares issued to ICS Opportunities LTD, Integrated Assets, LTD., Cayman Islands, and on and on.......take a peak at this SEC and you will see who is more than likely SHORT and crucifying SPPI and the shareholders: There is much fraud and deception going on with the trading of SPPI, IMO:


    CUSIP No.

    84763A108


    SCHEDULE 13G
    Page
    9
    of
    15

    Item 1.

    (a) Name of Issuer :



    Spectrum Pharmaceuticals, Inc., a Delaware corporation (the "Issuer").



    (b) Address of Issuer’s Principal Executive Offices :





    11500 South Eastern Avenue, Suite 240
    Henderson, Nevada 89052

    Item 2.
    (a) Name of Person Filing :

    (b) Address of Principal Business Office :

    (c) Citizenship :


    Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware



    ICS Opportunities, Ltd.
    c/o Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Cayman Islands



    Integrated Assets, Ltd.
    c/o Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Cayman Islands



    Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware



    Millennium International Management GP LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware



    Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware



    Israel A. Englander
    c/o Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: United States


    (d) Title of Class of Securities :

    common stock, par value $0.001 per share ("Common Stock")


    (e) CUSIP Number:

    84763A108


    CUSIP No.

    84763A108


    SCHEDULE 13G

    Sentiment: Strong Buy

  • Reply to

    I'm shocked

    by bioblitz1 May 16, 2014 10:00 AM
    sherrysgone sherrysgone May 16, 2014 12:25 PM Flag

    Just Google this outfit and you'll see that they are just a bunch of ambulance chasers, as we all well know!

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 15, 2014 2:25 PM Flag

    IMO, the article certainly didn't hurt and perhaps stabilized the price of SPPI in an angry market today!

    As for the cat video.....I loved it.....that was Candy's own Zevie (*~*)

    Sentiment: Strong Buy

  • Reply to

    Today in Vegas

    by astro_apprentice May 13, 2014 5:29 PM
    sherrysgone sherrysgone May 14, 2014 2:04 PM Flag

    Ha.....I was thinking about that earlier. Good job, String!

    Sentiment: Strong Buy

  • Reply to

    Forbes Article just hit

    by tartiaboy May 14, 2014 11:55 AM
    sherrysgone sherrysgone May 14, 2014 12:21 PM Flag

    Time to jerk the shorts around awhile!!

    Sentiment: Strong Buy

  • Reply to

    Forbes Article just hit

    by tartiaboy May 14, 2014 11:55 AM
    sherrysgone sherrysgone May 14, 2014 12:15 PM Flag

    Why This Little-Known Biotech Is An Enticing Takeover And New-Products Playat Forbes(Wed 11:48AM EDT)

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 13, 2014 12:01 PM Flag

    What a bunch of BS MANIPULATION going on. Not only does American Bulls say you should be buying SPPI, Market Edge, 2nd Opinion says SPPI is under accumulation!! I s 'pose that once the Tutes, who are short, finagle their positions around, we will start going up higher where we belong!!

    Sentiment: Strong Buy

  • SPPI
    SPECTRUM PHARMACEUTICALS
    BUY
    Last Pattern: BULLISH STOP LOSS
    Last Close:
    7.5900
    Change:
    +0.2900
    Percent change
    +3.97%
    6 mo. Rating 2★
    $100⇨ 127.19
    12 mo. Rating 2★
    $100⇨ 186.92
    24 mo. Rating
    $100⇨ 145.33
    Signal Update
    Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed the Stop Loss level which was at 7.2600, and our valid average buying price stands now at 7.3390. The previous SHORT recommendation was issued on 5/7/2014, 5 days ago, when the stock price was 6.9710. Since then SPPI has risen by +5.28%.
    Market Outlook
    We cannot deny bullish sentiment in the market anymore. It is wiser to hear the call of the market and change positions accordingly. The bullish stop loss is finally confirmed and a BUY signal is generated. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.

    Sentiment: Strong Buy

  • Spectrum Pharma Up on Q1 Earnings
    Zacks
    By Zacks Equity Research 1 hour ago

    Spectrum Pharmaceuticals’ (SPPI) shares are on a high since the announcement of its first-quarter results on May 8. The stock has gained over 5% so far. Spectrum Pharma’s first quarter 2014 earnings (excluding stock-based compensation, depreciation and other special items) of a penny per share were flat year over year.

    Spectrum Pharma however reported a first quarter 2014 loss (including stock-based compensation and depreciation but excluding other special items) of 3 cents per share, narrower than the year-ago loss of 4 cents. The Zacks Consensus Estimate was a loss of 21 cents per share for the reported quarter.

    Spectrum Pharma’s revenues in the first quarter 2014 came in at $40.1 million, up 3.8% year over year. The increase in revenues was attributable to higher product sales. Revenues were in line with the Zacks Consensus Estimate.

    Quarter in Details

    Spectrum Pharma recorded quarterly revenues from product sales and licensing fees during the quarter. Product revenues in the reported quarter were up 36.6% year over year to $40.1 million. This consisted of revenues from Fusilev, Folotyn, Zevalin and Marqibo.

    Fusilev sales were up 88% to $29.3 million in the reported quarter. The drug is approved for the treatment of metastatic colorectal cancer. Spectrum Pharma expects Fusilev sales to remain in the range of $20−$25 million per quarter in the forthcoming quarters.

    Sales from Folotyn, which was added to Spectrum Pharma’s portfolio following its acquisition of Allos Therapeutics, Inc. in Sep 2012, came in at $10.1 million in the first quarter. Folotyn is available in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (:PTCL). The demand for the drug remained in the range of $20−$25 million over the last few quarters.

    Zevalin sales during the reported quarter came in at $6.3 million, down 13.7% sequentially due to a slow start in Jan 2014. In Apr 2012, Spectrum Pharma acquired the licensing rights to market Zevalin outside the U.S. Zevalin is currently marketed for the treatment of non-Hodgkin's lymphoma. Spectrum Pharma is looking to expand the drug’s label. Zevalin is being studied in a phase III (:ZEST) study as a consolidation therapy for the treatment of patients suffering from diffuse large B-cell lymphoma.

    Marqibo, launched in the U.S. for the treatment of adults suffering from Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) during late third quarter 2013, contributed $1.5 million to the company’s net revenues in the first quarter 2014. Spectrum Pharma gained worldwide rights to Marqibo following the completion of the acquisition of California-based Talon Therapeutics in Jul 2013. Marqibo is also being developed for the treatment of non-Hodgkin's lymphoma.

    The company’s adjusted research and development (R&D) expenses of $11.7 million during the quarter were up 8.6% year over year. Adjusted selling, general and administrative (SG&A) expenses of $23.0 million were up 6.2%.

    Outlook

    Spectrum Pharma still expects its R&D expenses in 2014 to go up from the 2013 figure of $46.6 million due to higher clinical development activities. Meanwhile SG&A expenses are expected to remain stable for the remaining quarters of 2014.

    Other Developments

    The FDA is reviewing Spectrum Pharma’s application for Beleodaq (relapsed or refractory peripheral T-cell lymphoma) on a priority basis and a final decision from the U.S. regulatory body on the approval of the candidate is expected by Aug 9, 2014. The company expects to launch the candidate in the third quarter of 2014 depending on approval. Furthermore, the company plans to file for Captisol-enabled melphalan (a conditioning agent for stem cell transplant and multiple myeloma) in the third quarter of 2014.

    Our Take

    We are encouraged by Fusilev’s turnaround since the second half of last year after a disappointing first half. Fusilev has been the key revenue generator for Spectrum Pharma. We are also pleased with the company’s efforts to expand its product portfolio and pipeline.

    Spectrum Pharma currently carries a Zacks Rank #1 (Strong Buy). Some other stocks worth considering include Gilead Sciences Inc. (GILD), Ariad Pharmaceuticals Inc. (ARIA) and Alexion Pharmaceuticals, Inc. (ALXN). While Gilead carries a Zacks Rank #1 (Strong Buy), Ariad and Alexion carries a Zacks Rank #2.

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 10, 2014 9:57 PM Flag

    Thank you, String, for your very nice comments. I value your input along with many, many other very knowledgeable people on this MB!

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 9, 2014 10:40 AM Flag

    WOW......someone just scooped up 100,000 shares in about a minute or less!!

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 9, 2014 10:01 AM Flag

    I'm in for the long haul! Appreciate everyone's input yesterday about the earnings release and the conference call. I'll just sit back and read what you knowledgeable people have to say from now on (mostly)!!

    GLTA longs!

    Sherry

    Sentiment: Strong Buy

  • Reply to

    why SPPI???

    by matrixtrade123 May 2, 2014 9:56 AM
    sherrysgone sherrysgone May 3, 2014 10:49 PM Flag

    Nice post, String. Not everyone is a daytrader. Some of us actually hold stocks for a very long time and what you say is soooooooooo true. I bought TASR at $40, it split and went waaaaaaaaaaaay down into the 3's. I bought more all the way down until I got tired of buying it. Tucked it in my drawer (head) and guess what, it came roaring back clear up to $19+ within the past year. Of course, I sold B4 it reached that level, but was one of my best performers last year

    . BTW, I think most of you on here are smart enough to know that when some of us post our sentiment, we post our "Long-Term Sentiment" not a daily sentiment. I am a long term investor and when I say "Strong Buy," it is my sentiment for long-term, and that is what YHOO asks for. Everyone knows not to buy or sell based on what someone on an anonymous MB says. Geez, can't believe we have so many dumb posters that come on here now and then bloviating how some MB posters are causing others to lose money!!! Furthermore, there are many, many posters on this MB who present absolutely fantastic info about SPPI, such as Ouch, Antihama, TTB, Csat, our newcomer, caveman.smile, Taylor, Candy, Hneiman, String, now that he's back, and on and on. I would base my BUY decisions on what they say more than some silly old lady who has a long term Strong Buy. That's my sentiment.....you decide for yourself how you believe and what sentiment you have. I'm certainly not buying or selling on ANYONE's sentiment on this or any other MB. Hopefully, most people have the good sense to decide for themselves whether they want to buy, sell or hold!

    Cheers...............

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 3, 2014 7:36 AM Flag

    Wow, Joe......which short HF is giving you ur talking points? You've been a member since April 14 & sure act like ur an authority about Raj & management!. Y"all just keep repeating the same ol" #$%$. Don't any of you short bashers have anything new? UR boss needs to come up w/some better material!

    Sentiment: Strong Buy

  • Reply to

    why SPPI???

    by matrixtrade123 May 2, 2014 9:56 AM
    sherrysgone sherrysgone May 2, 2014 11:41 AM Flag

    Maxipad......we're just tired of all you #$%$ coming on our MB trying to influence others not to buy SPPI or to sell SPPI when you are on other MB's pumping your stock. We all want to make money and don't go on your MB's bashing your stock. I admit that I have gone on Shortdick and Imho's MB bashing them B4, but not their stock. I want others to make money and I find you, Shortdick and IMHO, et al to be very repulsive people when you can't let go because you either lost money on the stock or you are a short or perhaps even a paid basher!!

    Sentiment: Strong Buy

  • sherrysgone sherrysgone May 2, 2014 10:54 AM Flag

    And this is why I quite often think the markets are just a bunch of "bull malarkey!"......nothing has changed about the value of SPPI.....still waaaaaaaaaay undervalued. If the Dow, Nasdaq & S&P start going down, I guess that's a signal that everything is s'posed to go down. People think if they trash talk Raj, that's going to make the stock go down and on and on and on. Let the games begin. Oh, they're already on!

    Sentiment: Strong Buy

DKS
44.86-1.04(-2.27%)4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.